

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (gh-117) VENGLUSTAT MALATE


PRONUNCIATION ven gloo' stat

THERAPEUTIC CLAIM Treatment of Fabry disease (FD), Gaucher disease type 3 (GD3); Glucocerebrosidase gene-Associated Parkinson Disease (GBA-PD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD)

CHEMICAL NAMES

1. Butanedioic acid, 2-hydroxy-, (2S)-, compd. with (3S)-1-azabicyclo[2.2.2]oct-3-yl *N*-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]carbamate (1:1)
2. (3S)-1-azabicyclo[2.2.2]octan-3-yl *N*-{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate (2S)-2-hydroxybutanedioate salt (1:1)

STRUCTURAL FORMULA



MOLECULAR FORMULA  $C_{20}H_{24}FN_3O_2S \cdot C_4H_6O_5$

MOLECULAR WEIGHT 523.6

TRADEMARK None as yet

SPONSOR Sanofi

CODE DESIGNATIONS SAR402671A, GZ/SAR402671A, Genz-682452-AU

CAS REGISTRY NUMBER 1629063-78-0

UNII 94855LQZ8D

gbk